Bülent YARDIMCI
(İstanbul Florence Nightingale Hastanesi, İstanbul, Türkiye)
Tevfik ECDER
(İstanbul Bilim Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Nefroloji Bilim Dalı, İstanbul, Türkiye)
Yıl: 2019Cilt: 28Sayı: 1ISSN: 1300-7718 / 2667-4440Sayfa Aralığı: 75 - 80İngilizce

10 0
Smoking and Chronic Kidney Disease
Smoking is the leading preventable cause of death worldwide. Smoking affects all systems of the organism. Smoking stimulates the sympathetic nervous system, increases blood pressure and albuminuria, and decreases renal function. Smoking increases renal functional loss in patients with chronic kidney disease. Moreover, smoking accelerates the course of atherosclerosis, causing cardiovascular complications and premature death. Smoking decreases graft survival in kidney transplant patients. As a result, all physicians and health care providers should acknowledge all patients who smoke about the deleterious effects of smoking and continuously motivate them to stop smoking.
DergiDerlemeErişime Açık
  • 1. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997; 51: 1669-77. [CrossRef]
  • 2. Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663-72. [CrossRef]
  • 3. Ritz E, Benck U, Franek E, Keller C, Seyfarth M, Clorius J. Effects of smoking on renal hemodynamics in heathy volunteers and in patients with glomerular disease. J Am Soc Nephrol 1998; 9: 1798- 804.
  • 4. Gambaro G, Verlato F, Budakovic A, Casara D, Saladini G, Del Prete D, et al. Renal impairment in chronic cigarette smokers. J Am Soc Nephrol 1998; 9: 562-7.
  • 5. Janssen WM, Hillege H, Pinto-Sietsma SJ, Bak AA, De Zeeuw D, de Jong PE, et al. Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. Clin Chem Lab Med 2000; 38: 1107-10. [CrossRef]
  • 6. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular mortality. J Intern Med 2001; 249: 519-26. [CrossRef]
  • 7. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133: 585-91. [CrossRef]
  • 8. Halimi JM, Giraudeau B, Vol S, Caces E, Nivet H, Lebranchu Y, Tichet J. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285-92. [CrossRef]
  • 9. Briganti EM, Branley P, Chadban SJ, Shaw JE, McNeil JJ, Welborn TA, et al. Smoking is associated with renal impairment and proteinuria in the normal population: The AusDiab Kidney Study. Am J Kidney Dis 2002; 40: 704-12. [CrossRef]
  • 10. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: Risk factors for renal functional decline in an older population. Kidney Int 2000; 57: 2072-9. [CrossRef]
  • 11. Maeda I, Hayashi T, Sato KK, Koh H, Harita N, Nakamura Y, et al. Cigarette smoking and the association with glomerular hyperfiltration and proteinuria in healthy middle-aged men. Clin J Am Soc Nephrol 2011; 6: 2462-9. [CrossRef]
  • 12. Ejerblad E, Fored CM, Lindblad P, Fryzek J, Dickman PW, Elinder CG, et al. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol 2004; 15: 2178-85. [CrossRef]
  • 13. Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int 2011; 80: 516-23. [CrossRef]
  • 14. Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y, et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant 2017; 32: 475-87. [CrossRef]
  • 15. Mimran A, Ribstein J, DuCailar G, Halimi JM. Albuminuria in normals and essential hypertension. J Diabetes Complications 1994; 8: 150-6. [CrossRef]
  • 16. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Hallé JP, Hoogwerf B, et al. Prevalence and determinants of microalbuminuria in highrisk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000; 23: B35-9.
  • 17. Wachtell K, Olsen MH, Dahlof B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. J Hypertens 2002; 20: 405-12. [CrossRef]
  • 18. Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35: 687-94. [CrossRef]
  • 19. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1978; 1: 146-9. [CrossRef]
  • 20. Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T. Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 1984; 215: 63-8. [CrossRef]
  • 21. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991; 265: 614-7. [CrossRef]
  • 22. Klein R, Klein BE, Moss SE. Incidence of gross proteinuria in older-onset diabetes. A population-based perspective. Diabetes 1993; 42: 381-9. [CrossRef]
  • 23. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126-31. [CrossRef]
  • 24. Chuahirun T, Wesson DE. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis 2002; 39: 376-82. [CrossRef]
  • 25. Whelton PK, Randall B, Neaton J, Stamler J, Brancati FL, Klag MJ: Cigarette smoking and ESRD incidence in men screened for the MRFIT. J Am Soc Nephrol 1995; 6: 408A.
  • 26. Stengel B, Couchoud C, Cenee S, Hemon D: Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies. Kidney Int 2000; 57: 2519-26. [CrossRef]
  • 27. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1349-54.
  • 28. Ozkok A, Akpinar TS, Tufan F, Kanitez NA, Uysal M, Guzel M, Caliskan Y, Alisir S, Yazici H, Ecder T: Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol 2013; 17: 345-51. [CrossRef]
  • 29. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082-8. [CrossRef]
  • 30. Orth SR, Stöckmann A, Conradt C, Ritz E, Ferro M, Kreusser W, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926-31. [CrossRef]
  • 31. Textor SC, Wilcox CS. Renal artery stenosis: A common, treatable cause of renal failure? Annu Rev Med 2001; 52: 421-42. [CrossRef]
  • 32. Metcalfe W, Reid AW, Geddes CC. Prevalence of angiographic atherosclerotic renal artery disease and its relationship to the anatomical extent of peripheral vascular atherosclerosis. Nephrol Dial Transplant 1999; 14: 105-8. [CrossRef]
  • 33. Appel RG, Bleyer AJ, Reavis S, Hansen KJ: Renovascular disease in older patients beginning renal replacement therapy. Kidney Int 1995; 48: 171-6. [CrossRef]
  • 34. Black HR, Zeevi GR, Silten RM, Walker Smith GJ. Effect of heavy cigarette smoking on renal and myocardial arterioles. Nephron 1983; 34: 173-9. [CrossRef]
  • 35. Main J. How important is atheromatous renal artery stenosis as a cause of end-stage renal disease. Semin Dial 2001; 14: 143-5.[CrossRef]
  • 36. Baggio B, Budakovic A, Casara D, Gambaro G, Saladini G, et al. Renal involvement in subjects with peripheral atherosclerosis. J Nephrol 2001; 14: 286-92.
  • 37. Drummond CA, Brewster PS, He W, Ren K, Xie Y, Tuttle KR, et al. Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis. PloS One 2017: 1-15. [CrossRef]
  • 38. Foley RN, Herzoc CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study. Kidney Int 2003; 63: 1462-7. [CrossRef]
  • 39. Orth SR, Uehlinger DE. Smoking and dialysis: A dreadful scenario for the cardiovascular system? Kidney Int 2003; 63: 1580-1. [CrossRef]
  • 40. Liebman SE, Lamontagne SP, Huang L-S, Messing S, Bushinsky DA. Smoking in dialysis patients: A systematic review and meta-analysis of mortality and cardiovascular morbidity. Am J Kidney Dis 2011; 58: 257-65. [CrossRef]
  • 41. Aref A, Sharma A, Halawa A: Smoking in renal transplantation; Facts beyond myth. World J Transplant 2017; 7: 129-33. [CrossRef]
  • 42. Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 2001; 71: 1752-7. [CrossRef]
  • 43. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A: Risk factors for late allograft failure. Kidney Int 2002; 62: 1848-54. [CrossRef]
  • 44. Zitt N, Kollerits B, Neyer U, Mark W, Heininger D, Mayer G, et al. Cigarette smoking and chronic allograft nephropathy. Nephrol Dial Transplant 2007; 22: 3034-9. [CrossRef]
  • 45. Heldt J, Torrey R, Han D, Baron P, Tenggardjaja C, McLarty J, et al. Donor smoking negatively affects donor and recipient renal function following living donor nephrectomy. Adv Urol 2011; 929263. [CrossRef]
  • 46. Orth SR, Hallan SI. Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients - Absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008; 3: 226-36. [CrossRef]
  • 47. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross M-L, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-78.
  • 48. Hansen KW, Pedersen MM, Christiansen JS, Mogensen CE. Night blood pressure and cigarette smoking: disparate association in healthy subjects and diabetic patients. Blood Press 1994; 3: 381-88.[CrossRef]
  • 49. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes – A systematic review and meta-analysis. JAMA 2007; 298: 2654-64. [CrossRef]
  • 50. Nasr SH, D’Agati VD. Nodular glomerulosclerosis in the non-diabetic smoker. J Am Soc Nephrol 2007; 18: 2032-6. [CrossRef]
  • 51. Hua P, Feng W, Ji S, Raij L, Jaimes EA. Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol 2010; 299: F732-9. [CrossRef]
  • 52. Jaimes EA, Tian RX, Raij L. Nicotine: the link between cigarette smoking and the progression of renal injury? Am J Physiol Heart Circ Physiol 2007; 292: H76-82 [CrossRef]
  • 53. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997; 94: 13915-20. [CrossRef]
  • 54. Lan L, Han Y, Ren W, Jiang J, Wang P, Hu Z. Advanced glycation endproducts affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras-related C3 botulinum toxin substrate 1 signaling pathway. Mol Med Rep 2015; 11: 4321-6. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.